Moreover, if these results were integrated with pathological data—such as PR negativity, lymphovascular invasion, and high Ki-67—valuable information could be obtained for differentiating patients with ER-positive, HER2-negative breast cancer who would benefit from adjuvant chemotherapy and endocrine treatment, especially if Oncotype DX testing is unavailable. This evidence concerns the gene ERBB2 and breast carcinoma.